Research
Hormonal
Roux-en-Y gastric bypass (RYGB) surgery effectively reduces the defended level of body fat mass by altering gut-brain communication, increasing anorexigenic gut peptides, and reducing food reward valuation.
For morbid obesity, Roux-en-Y gastric bypass is the most effective treatment, significantly reducing the body's defended fat mass set point. It works by altering gut hormones and reducing food reward, leading to sustained weight loss.
StrongSupportsHIGH confidence
RYGB causes a reduction in hunger, reduced cravings for energy dense foods... it appears to be the only well-characterized medical treatment that substantially, reliably, and durably reduces the defended level of fat mass.
Why this rating
Based on a clinical review of high-quality evidence regarding bariatric surgery outcomes.
Source
Regulation of Food Intake, Energy Balance, and Body Fat Mass: Implications for the Pathogenesis and Treatment of Obesity
Stephan J. Guyenet et al. · The Journal of Clinical Endocrinology & Metabolism · 2012
DOI 10.1210/jc.2011-2525
narrative_reviewCited 278×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity involves the biological defense of an elevated body fat mass set point, driven by homeostatic mechanisms that resist fat loss through increased hunger and metabolic efficiency.Strong
- Hypothalamic inflammation and neuronal injury, triggered by high-fat diets and elevated lipid metabolites, contribute to leptin resistance and the defense of elevated body fat mass.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →